Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients

Niedźwiecki, Sebastian; Stępień, Tomasz; Kuzdak, Krzysztof; Stępień, H; Krupiński, Roman; Seehofer, Daniel; Rayes, Nada; Ulrich, Frank

doi:10.1007/s00423-007-0251-9

Cited by 18 publications

(14 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, the IL-1 antagonist, IL-1Ra has been shown to be overexpressed in multiple cancers, including multiple myeloma, leukemia, cervical, ovarian, colorectal, pancreatic and breast cancer, [53][54][55][56][57][58] but to be downregulated in others. 59 Similarly, high expression of the IL-1ra correlates with either better 54,56,[60][61][62][63] or worse cancer prognosis 62,64,65 This variability could stem from differential requirements of the two IL-1 cytokines in different cancers. Using KM plotter we have found that breast cancer patients expressing high levels of IL-1a had a better prognosis compared with patients expressing low levels of this cytokine, 48 consistent with a role of IL-1a as a negative regulator of tumorigenesis.…”

Section: Discussionmentioning

confidence: 99%

The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis

et al. 2017

View full text Add to dashboard Cite

Breast cancer is the most common cancer in women and the second leading cause of female cancerrelated deaths worldwide. Inflammation is an established hallmark of tumorigenesis and an important determinant of tumor outcome and response to therapy. With advances in cancer immunotherapy, there is an urgent need to dissect the contribution of specific immune effectors in cancer development. Here, we genetically investigated the role of the Interleukin-1 (IL-1) receptor 1 (IL-1R1) pathway in breast cancer tumorigenesis and metastasis using the MMTV-PyMT mouse model. Our results indicate that IL-1R1 signaling suppresses mammary tumor cell proliferation early in tumorigenesis and curbs breast cancer outgrowth and pulmonary metastasis. We show that PyMT/Il1r1 ¡/¡ mice had a higher primary tumor burden and increased mortality rate compared with IL-1R1-sufficient PyMT control mice. This phenotype was independent of the inflammatory caspases-1/-11 but driven by IL-1a, as PyMT/ Il1a ¡/¡ mice phenocopied PyMT/Il1r1 ¡/¡ mice. Collectively, our results suggest that IL-1a-mediated IL-1R1 signaling is tumor-suppressive in PyMT-driven breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It should also be noticed that IL1RA is an acute phase marker and high levels have previously been associated with aggressive disease and/or adverse prognosis in various malignancies, including T cell lymphoma [ 82 ], sarcoma [ 83 ], colorectal cancer [ 84 , 85 ], and thyroid cancer [ 86 ]. Our present study is the first to suggest that this is true also in HNSCC.…”

Section: Discussionmentioning

confidence: 99%

The Acute Phase Reaction and Its Prognostic Impact in Patients with Head and Neck Squamous Cell Carcinoma: Single Biomarkers Including C-Reactive Protein Versus Biomarker Profiles

et al. 2020

View full text Add to dashboard Cite

C-reactive protein (CRP) has a prognostic impact in head and neck squamous cell carcinoma (HNSCC). However, the acute phase reaction involves many other proteins depending on its inducing events, including various cytokines that can function as reaction inducers. In the present study, we compared the pretreatment acute phase cytokine profile for 144 patients with potentially curative HNSCC. We investigated the systemic levels of interleukin (IL)6 family mediators (glycoprotein (gp130), IL6 receptor (R)α, IL6, IL27, IL31, oncostatin M (OSM), ciliary neurotrophic factor (CNTF)), IL1 subfamily members (IL1R antagonist (A), IL33Rα), and tumor necrosis factor (TNF)α. Patient subsets identified from this 10-mediator profile did not differ with regard to disease stage, human papilloma virus (HPV) status, CRP levels, or death cause. Increased CRP, IL6, and IL1RA levels were independent markers for HNSCC-related death in the whole patient population. Furthermore, gp130, IL6Rα, and IL31 were suggested to predict prognosis among tumor HPV-negative patients. Only IL6 predicted survival in HPV-positive patients. Finally, we did a clustering analysis of HPV-negative patients based on six acute phase mediators that showed significant or borderline association with prognosis in Kaplan–Meier analyses; three subsets could then be identified, and they differed in survival (p < 0.001). To conclude, (i) HPV-negative and HPV-positive HNSCC patients show similar variations of their systemic acute phase profiles; (ii) the prognostic impact of single mediators differs between these two patient subsets; and (iii) for HPV-negative patients, acute phase profiling identifies three patient subsets that differ significantly in survival.

show abstract

“…Importantly, increased levels of IL-1Ra were observed in numerous malignancies, including colorectal cancer (Iwagaki et al, 1997;Ito and Miki, 1999;Kaminska et al, 2000), multiple myeloma (Gherardi et al, 1996), ovarian cancer (Mustea et al, 2008), leukemia (Barak et al, 1998), cervical carcinoma (Fujiwaki et al, 2003), pancreatic cancer (Ebrahimi et al, 2004;Poch et al, 2007), uveal melanoma (Lee et al, 2012), prostate cancer (Parekh et al, 2007), breast cancer (Lv et al, 2011), and thyroid cancer (Niedźwiecki et al, 2008). It is interesting that elevated concentrations of IL-1Ra were associated either with greater (Iwagaki et al, 1997;Ito and Miki, 1999;Kaminska et al, 2000;Fujiwaki et al, 2003;Parekh et al, 2007;Niedźwiecki et al, 2008) or lesser (Gherardi et al, 1996;Parekh et al, 2007;Poch et al, 2007) disease severity.…”

Section: Il-1ra Restrains Il-1mentioning

confidence: 99%

Interleukin-1 Superfamily and Cancer

Yuzhalin¹,

Kutikhin²

2015

Interleukins in Cancer Biology

View full text Add to dashboard Cite

Serum levels of interleukin-1 receptor antagonist (IL-1ra) in thyroid cancer patients

Abstract: The findings of our study indicate that IL-1ra may play an important role in the development of ATC and FTC. Future efforts should focus on the possible application of IL-1ra as a biomarker for the above-mentioned thyroid malignancies.

Cited by 18 publications

References 36 publications

The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis

The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis

The Acute Phase Reaction and Its Prognostic Impact in Patients with Head and Neck Squamous Cell Carcinoma: Single Biomarkers Including C-Reactive Protein Versus Biomarker Profiles

Interleukin-1 Superfamily and Cancer

Contact Info

Product

Resources

About